RemeGen : INSIDE INFORMATION ANNOUNCEMENT - NATIONAL MEDICAL PRODUCTS ADMINISTRATION GRANTED CONDITIONAL MARKETING APPROVAL FOR TELITACICEPT TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) IN CHINA

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

RemeGen Co., Ltd.*

࿲׹͛يႡᖹ€๧ٰ̨΅Ϟࠢʮ̡

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 9995)

INSIDE INFORMATION ANNOUNCEMENT

NATIONAL MEDICAL PRODUCTS ADMINISTRATION GRANTED CONDITIONAL MARKETING APPROVAL FOR TELITACICEPT (BRAND

NAME: 泰爱 ®)

TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) IN CHINA

This announcement is made by RemeGen Co., Ltd.* ࿲׹͛يႡᖹ€๧ٰ̨΅Ϟࠢʮ̡ (the "Company", together with its subsidiaries, the "Group") pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the "Board") is pleased to announce that telitacicept (RC18, Brand Name: 泰爱®), the dual targeted TACI-Fc fusion protein independently developed in-house by the Company, has been granted conditional marketing approval by the National Medical Products Administration of the People's Republic of China for the treatment of patients with Systemic Lupus Erythematosus (SLE).

The grant of marketing approval for telitacicept (RC18, Brand Name: 泰爱®) is a significant accomplishment of the Group. It signifies the Group's achievements in the field of autoimmune diseases. It also demonstrates the Group's ability to develop biologic drugs and reflects the Group's strong in-house research and development capabilities.

SLE has one of the highest mortality and disability rates among autoimmune rheumatic diseases. According to Frost & Sullivan, the global SLE prevalence was approximately 7.7 million in 2019, and it is estimated to reach 8.6 million by 2030. In China, there were approximately 1.0 million SLE patients in 2019, which is estimated to grow to approximately 1.1 million by 2030. According to Frost & Sullivan, the market size of global SLE biological therapeutics is estimated to grow at a CAGR of 26.8% from US$0.8 billion in 2019 to US$10.8 billion by 2030. Telitacicept is the second innovative biologics drug approved to treat SLE in China over the past 60 years.

ABOUT TELITACICEPT (RC18, 泰爱 ®)

Telitacicept is a proprietary novel fusion protein of us to treat autoimmune diseases. It is constructed with the extracellular domain of the human transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) receptor and the fragment crystallizable (Fc) domain of human immunoglobulin G (IgG). Telitacicept targets two cell-signaling molecules critical for B-lymphocyte development: B-cell lymphocyte stimulator (BLyS) and a proliferation inducing ligand (APRIL), which allows it to effectively reduce B-cell mediated autoimmune responses that are implicated in several autoimmune diseases. We are currently conducting a number of phase II or III clinical studies for telitacicept to treat other indications within the autoimmune disease area, in an attempt to address the significant unmet or underserved medical needs in this therapeutic area.

Warning under Rule 18A.05 of the Listing Rules: There is no assurance that the telitacicept (RC18) will ultimately be successfully marketed by the Company. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board RemeGen Co., Ltd. Mr. Wang Weidong Chairman and executive director

Yantai, The People's Republic of China

March 11, 2021

As at the date of this announcement, the Board of the Company comprises Mr. Wang Weidong, Dr. Fang Jianmin, Dr. He Ruyi and Mr. Lin Jian as the executive directors, Dr. Wang Liqiang and Dr. Su Xiaodi as the non-executive directors, and Ms. Yu Shanshan, Mr. Hao Xianjing and Dr. Lorne Alan Babiuk as the independent non-executive directors.

* For identification purposes only